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Abstract
The cyclic production of estrogen and progesterone by the premenopausal ovary accounts
for the steep rise in breast cancer risk in premenopausal women. These hormones are breast
cell mitogens. By reducing exposure to these ovarian hormones, agonists of luteinizing
hormone-releasing hormone (LHRH) given to suppress ovarian function may prove useful in
cancer prevention. To prevent deleterious effects of hypoestrogenemia, the addition of low-
dose hormone replacement to the LHRH agonist appears necessary. Pilot data with such
an approach indicates it is feasible and reduces mammographic densities.
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Introduction
More than a decade ago Pike et al [1•] first suggested a
potential role for agonists of LHRH to prevent breast
cancer. The rationale for considering LHRH agonists is
due to their ability to suppress ovarian function and sex
steroid production; the reduction in sex steroids is pre-
dicted to lead to the prevention of breast cancer.
Ovarian hormones
Ovarian hormones (estrogens and progestogens) are criti-
cal factors in the genesis of human breast cancer. During
the premenopausal years breast cancer risk increases
steeply, but after cessation of ovarian function
(menopause) it increases at a much lower rate. Epidemio-
logic studies have clearly demonstrated that early
menopause, whether natural or artificial (bilateral oophorec-
tomy), substantially reduces breast cancer risk. Menopause
before age 35 years is associated with a 60–75% reduc-
tion in breast cancer risk [2–6]. The calculated effect of an
early oophorectomy on the age–incidence curve of breast
cancer is given in Figure 1; age at menopause determines
the transition point from the steeply rising premenopausal
slope to the more gentle postmenopausal slope. The pro-
tective effect of oophorectomy on breast cancer risk has
recently been shown in women carrying BRCA1 germline
mutations. Bilateral prophylactic oophorectomy (done to
prevent ovarian cancer) is associated with a reduction in
breast cancer risk [7]. The magnitude of the protection
reported by Rebbeck et al [7] is substantial (hazard ratio of
0.53) and increased with increasing duration of follow up
after the prophylactic surgery.
The effect of ovarian hormones on breast cancer risk is
predictable in light of the effects of these hormones on
breast epithelial cell proliferation. Cell proliferation is
central to the process of carcinogenesis, and agents that
increase cell proliferation increase the incidence of
random mutations and hence cancer risk [8]. In the normalhttp://breast-cancer-research.com/content/2/4/264
human breast epithelial cell, both estrogens and progesto-
gens are mitogens (for review [9•]), hence oophorectomy
reduces cancer risk by eliminating the breast mitogen
progesterone and reducing the estrogen levels.
Luteinizing hormone-releasing hormone
Native LHRH produced by the hypothalamus controls the
secretion of follicle-stimulating hormone and luteinizing
hormone by the pituitary gland, and hence gonadal steroid
hormone production. Administration of potent synthetic
agonists of LHRH to premenopausal women results in a
transient rise in follicle-stimulating hormone/luteinizing
hormone release, followed by a sustained suppression.
The reduction in serum estradiol and serum progesterone
to oophorectomized levels by LHRH agonists has been
demonstrated in numerous reports [10], and led to their
use in the treatment of hormone-responsive metastatic
breast cancer in premenopausal women. Although the role
of ovarian ablation in the management of early breast
cancer remains unsettled, evidence [11] indicates that
LHRH agonists may also prevent breast cancer recur-
rence in the adjuvant setting. Of particular interest is the
large multicenter trial that evaluated the LHRH agonist
goserelin in the adjuvant setting recently reported by
Baum [11]. In that study a substantially reduced incidence
of contralateral new primary breast tumors was reported.
Use of LHRH in premenopausal women is predictably
associated with hypoestrogenic symptoms, including hot
flushes, vaginal dryness, and sleep disturbances. A loss of
bone mineral density (BMD) has been seen in the majority
of studies that involved protracted (6 months) LHRH
agonist treatment. Because oophorectomy at a young age
is associated with an increased risk of cardiovascular
disease, the long-term use of a LHRH agonist is of
concern. Although the side effects and risks associated
with hypoestrogenemia are acceptable in the setting of
metastatic breast cancer and in the adjuvant treatment of
early breast cancer, such effects may not be acceptable to
women who are only at risk for the development of the
disease. A LHRH agonist given at a dose sufficient to sup-
press ovarian function to postmenopausal levels should
achieve a major reduction in a woman’s lifetime breast
cancer risk, but the benefit will only occur if the agent is
continued for prolonged periods of time.
In an effort to minimize the deleterious effects of hypo-
estrogenemia the addition of other agents, including bispho-
sphonates, selective estrogen receptor modulators, and
low-dose add-back sex steroids, is under consideration or
study. The rationale for bisphosphonates and selective
estrogen receptor modulators is related to their protective
effect on BMD. The tolerance of women to hypoestrogenic
symptoms remains to be evaluated, however.
Pike  et al [1•] suggested that the addition of low-dose
hormone replacement therapy (HRT) would reduce the
hypoestrogenic effects of the LHRH agonist, while pre-
serving the major reduction in cancer risk. The combined
LHRH agonist and low-dose hormone replacement results
in a reduction in estrogen exposure by 60% and in
progestogen exposure by 75% when compared to pre-
menopausal hormone levels. Because the add-back low-
dose hormone replacement should permit long-term use,
protracted reductions in hormone exposure is possible.
Table 1 shows that lifetime breast cancer risk is predicted
to be reduced by almost one-third if used for 5 years and
by more than 50% if used for 10 years. These figures for
breast cancer are calculated from a mathematical model
[1•,12,13], and include an effect of progestogen that is
consistent with that reported from recent studies of HRT
on breast cancer risk [14].
Clinical effects of luteinizing hormone-
releasing hormone agonists
In a pilot study designed to determine the effects of an
LHRH agonist plus low-dose replacement therapy, bone
Figure 1
Effect of oophorectomy on the age–incidence curve for breast cancer.
The calculations were made using the model described by Pike [12].
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Table 1
Predicted reduction in lifetime risk of cancer with the
prototype contraceptive
Duration of regimen (years)
Cancer type 5 10 15
Breast 31% 53% 70%
Endometrium 18% 33% 45%
Ovary 41% 67% 84%
The calculations were made using the model described by Pike [12],
and were based on using the regimen at any time after the first full-
term pregnancy and before age 40 years.Breast Cancer Research    Vol 2 No 4 Spicer and Pike
metabolism, lipoprotein metabolism, the endometrium, and
menopausal symptoms were evaluated in women predis-
posed to familial breast cancer [15,16]. The regimen
tested included a depot LHRH agonist administered
monthly, low-dose estrogen with conjugated estrogens
0.625–0.9mg for 6 days each week, and the progestogen
medroxyprogesterone acetate 10mg for 14 days every
112 days (4 months). Subsequently, the effects of replac-
ing ovarian androgen (which is also suppressed by LHRH
agonists) with the add-back hormone regimen were evalu-
ated. Subjects were premenopausal women, aged 25–40
years, with one of the following breast cancer risk factors:
lobular carcinoma in situ, mother and sister with breast
cancer (at least one premenopausal), or a mother or sister
with bilateral premenopausal breast cancer. Twenty-one
individuals were entered and were randomized on a 2:1
basis to a treatment group and a control group.
Overall the regimen was well tolerated [16]. A question-
naire assessed frequency and intensity of possible symp-
toms of menopausal distress and premenstrual syndrome.
Symptoms of menopausal distress were infrequent, and
the treated individuals had a decrease in luteal phase or
premenstrual syndrome symptoms of ‘abdominal bloating
or fullness’; ‘abdominal cramps or pain’; ‘breast swelling’;
‘breast pain or tenderness’; ‘anxious, tense, or nervous’;
‘irritable, angry, impatient’; and ‘mood swings’ [16].
During the first year of the study, a small but significant
2.9% reduction in lumbar spine BMD was noted in the
treated group. As a result the study was modified to
replace ovarian androgens suppressed by the LHRH using
methyltestosterone. The mean change in BMD in the
lumbar spine after the addition of the androgen is depicted
in Table 2. These results suggest that the addition of the
androgen may have an effect on maintenance of BMD.
The initial regimen was associated with favorable effects
on the lipids during the months when medroxyproges-
terone acetate was not administered. The addition of the
methyltestosterone eliminated the beneficial effect of the
regimen on lipoproteins. However, the changes in choles-
terol (compared with baseline values) were not different
from those in the control individuals. Oral methyltestos-
terone is not considered an optimal method for replace-
ment of ovarian androgens.
Scheduled bleeding occurred after most progestogen
administrations. Unscheduled bleeding or spotting
occurred infrequently, as depicted in Table 3. No endome-
trial hyperplasia was identified in the endometrial biopsies
performed at cycle 13 and cycle 25. Recovery of menses
was timed from the date of injection of the last dose of
depot LHRH. The mean time was 5 months and median
3.9 months, although 16 months passed before return of
menses in one individual.
In the pilot study changes in mammographic densities
were measured in women on the treatment regimen and in
the control women. Because mammographic classification
schemes are unable to distinguish fine changes that do
not cause a change in category, the study directly mea-
sured the changes in mammographic densities. The radiol-
ogists were masked both as to whether the mammograms
were from treated or control individuals and whether they
were baseline or follow-up studies [17]. Figure 2 shows
the substantial improvement overall in the treated group.
The reduced estrogen and progestogen exposures
achieved by the regimen resulted in significant reductions
in follow-up mammographic densities. Epidemiologic
studies [18–21] have consistently found that increased
mammographic densities are associated with greater risk
independent of other breast cancer risk factors. The signif-
icant mammographic changes further support the evi-
dence that an LHRH agonist and low-dose add-back HRT
may contribute significantly to breast cancer reduction; a
second study in high-risk women is ongoing.
Conclusion
The risk of breast cancer rises steeply during the pre-
menopausal years. This is, in all likelihood, a result of
Table 2
Annualized change in BMD
Group Lumbar spine Femoral neck
Control 0.4% 0.2%
Treated with CE + MPA –2.9%† –2.2%‡
Treated with CE + MT + MPA 0% 1.6%
BMD was measured using quantitative digital radiography (Hologic Inc,
Waltham, MA, USA). CE, conjugated estrogens; MPA, medroxy-
progesterone acetate; MT, methyltestosterone. †P = 0.001,
‡P = 0.006.
Table 3
Unscheduled bleeding and spotting
Number of days/
Cycle 28-day cycle
number (mean [standard error]) Percentage of days
1–4 0.92 (0.28) 3.3
5–8 1.4 (0.37) 4.9
9–12 1.0 (0.38) 3.7
13–16 0.74 (0.38) 2.6
17–20 1.4 (0.45) 4.9
21–24 1.9 (0.91) 6.8http://breast-cancer-research.com/content/2/4/264
stochaistic mutations associated with ovarian hormone-
driven repetitive breast epithelial cell proliferation. A
regimen to reduce premenopausal exposure to estrogen
and progesterone based on suppression of ovarian func-
tion by an agonist of LHRH and replacement of low-dose
hormones would be expected to reduce breast cancer
risk. A pilot trial of such an approach demonstrated both
its feasibility and a beneficial reduction in mammographic
density. Studies are in progress to improve the acceptabil-
ity of the regimen and to test its effects on the mammo-
gram in high-risk women.
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Figure 2
Mammographic changes in treated and control individuals. Values are
expressed as median change from baseline and interquartile range.
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